Covered recipient · General Payments record
STUART HAL ISAACSON
Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2019 · Entire year
$782,978.05
706 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2019 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $307,685.09 | 122 |
| Consulting Fee | $131,828.45 | 32 |
| Education | $130,000.00 | 2 |
| Honoraria | $113,265.00 | 38 |
| Travel and Lodging | $84,144.80 | 222 |
| Food and Beverage | $16,054.71 | 290 |
By paying entity
PY2019 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Sunovion Pharmaceuticals Inc. | $140,958.74 | 7 |
| Teva Pharmaceuticals USA, Inc. | $130,376.86 | 116 |
| ACADIA Pharmaceuticals Inc | $108,447.97 | 114 |
| US WorldMeds, LLC | $107,211.88 | 162 |
| Acorda Therapeutics, Inc | $86,117.07 | 85 |
| Amneal Pharmaceuticals LLC | $45,268.83 | 38 |
| Adamas Pharmaceuticals, Inc. | $41,804.07 | 42 |
| Kyowa Hakko Kirin Co., Ltd | $30,281.05 | 8 |
| Neurocrine Biosciences, Inc. | $21,031.73 | 28 |
| Kyowa Kirin, Inc. | $20,750.94 | 26 |
| Lundbeck LLC | $18,578.36 | 23 |
| Allergan Inc. | $13,548.55 | 21 |
| AbbVie, Inc. | $9,299.75 | 20 |
| H. Lundbeck A S | $8,636.13 | 7 |
| Ipsen Biopharmaceuticals, Inc | $370.00 | 1 |
| Abbott Laboratories | $132.79 | 2 |
| Merz North America, Inc. | $95.61 | 2 |
| Avanir Pharmaceuticals, Inc. | $20.00 | 1 |
| Vertical Pharmaceuticals, LLC | $17.84 | 1 |
| ARBOR PHARMACEUTICALS, INC. | $17.34 | 1 |
| Mitsubishi Tanabe Pharma America, Inc. | $12.54 | 1 |
Page 13 of 15; records 601–650 of 706 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
STUART HAL ISAACSON
NPI 1023059169 · CMS profile ID 318175
Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology
BOCA RATON, FL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 13 of 15; records 601–650 of 706 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1023059169?year=2019&recipient=provider&page=13#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- STUART HAL ISAACSON, NPI 1023059169, CMS profile ID 318175. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 13 of 15; records 601–650 of 706 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1023059169?year=2019&recipient=provider&page=13#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- APA 7
- IndustryPayments. (2026). STUART HAL ISAACSON, NPI 1023059169, CMS profile ID 318175. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 13 of 15; records 601–650 of 706 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1023059169?year=2019&recipient=provider&page=13#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- Bluebook
- STUART HAL ISAACSON, NPI 1023059169, CMS profile ID 318175, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 13 of 15; records 601–650 of 706 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1023059169?year=2019&recipient=provider&page=13#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30
706 matching records · $782,978.05 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 601–650 of 706.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| US WorldMeds, LLC | $179.00 | 02/22/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 699441771 | CMS |
| US WorldMeds, LLC | $27.04 | 02/22/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 699441795 | CMS |
| US WorldMeds, LLC | $2.28 | 02/22/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 699441801 | CMS |
| US WorldMeds, LLC | $29.88 | 02/22/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 699441807 | CMS |
| US WorldMeds, LLC | $58.61 | 02/22/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 699441843 | CMS |
| US WorldMeds, LLC | $23.27 | 02/22/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 699441869 | CMS |
| US WorldMeds, LLC | $125.00 | 02/21/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 699441743 | CMS |
| US WorldMeds, LLC | $179.00 | 02/21/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 699441779 | CMS |
| US WorldMeds, LLC | $29.32 | 02/21/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 699441785 | CMS |
| US WorldMeds, LLC | $23.27 | 02/21/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 699441860 | CMS |
| Amneal Pharmaceuticals LLC | $18.28 | 02/20/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 692315729 | CMS |
| Avanir Pharmaceuticals, Inc. | $20.00 | 02/19/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 653570029 | CMS |
| Neurocrine Biosciences, Inc. | $125.00 | 02/16/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 693136901 | CMS |
| Neurocrine Biosciences, Inc. | $284.39 | 02/16/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 693136903 | CMS |
| Neurocrine Biosciences, Inc. | $44.56 | 02/16/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 693136905 | CMS |
| Neurocrine Biosciences, Inc. | $54.96 | 02/16/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 693136907 | CMS |
| Neurocrine Biosciences, Inc. | $59.42 | 02/16/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 693136909 | CMS |
| Neurocrine Biosciences, Inc. | $4,000.00 | 02/16/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 693136911 | CMS |
| Neurocrine Biosciences, Inc. | $42.92 | 02/16/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 693136913 | CMS |
| Neurocrine Biosciences, Inc. | $4.00 | 02/16/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 693136915 | CMS |
| Amneal Pharmaceuticals LLC | $3,250.00 | 02/15/2019 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 692315725 | CMS |
| Amneal Pharmaceuticals LLC | $1,625.00 | 02/15/2019 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 692315727 | CMS |
| Neurocrine Biosciences, Inc. | $438.60 | 02/15/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 693136897 | CMS |
| Neurocrine Biosciences, Inc. | $125.00 | 02/15/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 693136899 | CMS |
| Teva Pharmaceuticals USA, Inc. | $124.99 | 02/14/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 697882223 | CMS |
| Teva Pharmaceuticals USA, Inc. | $2,020.00 | 02/13/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 697882177 | CMS |
| Amneal Pharmaceuticals LLC | $809.39 | 02/12/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 692315723 | CMS |
| Teva Pharmaceuticals USA, Inc. | $117.71 | 02/12/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 697882229 | CMS |
| Allergan Inc. | $500.00 | 02/11/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 670575837 | CMS |
| Amneal Pharmaceuticals LLC | $114.33 | 02/11/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 692315721 | CMS |
| Teva Pharmaceuticals USA, Inc. | $57.04 | 02/11/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 697882095 | CMS |
| Teva Pharmaceuticals USA, Inc. | $3,030.00 | 02/11/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 697882119 | CMS |
| Teva Pharmaceuticals USA, Inc. | $301.01 | 02/11/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 697882161 | CMS |
| Teva Pharmaceuticals USA, Inc. | $194.67 | 02/09/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 697882179 | CMS |
| Amneal Pharmaceuticals LLC | $329.36 | 02/08/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 692315713 | CMS |
| Amneal Pharmaceuticals LLC | $2,500.00 | 02/08/2019 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 692315715 | CMS |
| Amneal Pharmaceuticals LLC | $328.29 | 02/08/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 692315717 | CMS |
| Amneal Pharmaceuticals LLC | $716.92 | 02/08/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 692315719 | CMS |
| Teva Pharmaceuticals USA, Inc. | $338.38 | 02/08/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 697882129 | CMS |
| Teva Pharmaceuticals USA, Inc. | $116.81 | 02/08/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 697882247 | CMS |
| US WorldMeds, LLC | $424.22 | 02/08/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 699441969 | CMS |
| US WorldMeds, LLC | $3,500.00 | 02/08/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 699441977 | CMS |
| Teva Pharmaceuticals USA, Inc. | $4,040.00 | 02/06/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 697882139 | CMS |
| US WorldMeds, LLC | $3.51 | 02/06/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 699441691 | CMS |
| US WorldMeds, LLC | $175.88 | 02/05/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 699441853 | CMS |
| US WorldMeds, LLC | $1,096.24 | 02/05/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 699441876 | CMS |
| US WorldMeds, LLC | $3,500.00 | 02/05/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 699441883 | CMS |
| US WorldMeds, LLC | $2,000.00 | 02/05/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 699441889 | CMS |
| Allergan Inc. | $15.93 | 02/04/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 670575833 | CMS |
| Teva Pharmaceuticals USA, Inc. | $147.60 | 02/04/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 697882135 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $230,485.30 | 5 |
| PY2025 | Principal investigator | $1,032,373.98 | 236 |
| PY2024 | Recipient | $347.11 | 2 |
| PY2024 | Principal investigator | $904,468.05 | 177 |
| PY2023 | Recipient | $686.00 | 2 |
| PY2023 | Principal investigator | $823,950.67 | 145 |
| PY2022 | Principal investigator | $675,119.76 | 190 |
| PY2021 | Recipient | $66.46 | 1 |
| PY2021 | Principal investigator | $911,612.70 | 259 |
| PY2020 | Recipient | $12,182.38 | 11 |
| PY2020 | Principal investigator | $816,737.56 | 247 |
| PY2019 | Recipient | $69,899.15 | 17 |
| PY2019 | Principal investigator | $1,420,795.13 | 330 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
241 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ABBVIE INC. | $1,780.16 | 12/31/2025 | Non-covered Recipient Entity RESEARCH INSTITUTE OF THE SOUTHEAST LLC | Multicenter, Evaluator-blinded, Randomized, Controlled Study of the Safety and Effectiveness of JUVEDERM VOLITE XC Injectable Gel for Improvement in Neck Appearance | No dispute reported | 06/30/2026 | 1202533213 |
| Principal investigator 1 | ABBVIE INC. | $600.00 | 12/31/2025 | Non-covered Recipient Entity PARKINSONS DISEASE AND MOVEMENT | An open-label extension of Study M15-741 to evaluate the safety and tolerability of 24-hour daily exposure of continuous subcutaneous infusion of ABBV-951 in subjects with Parkinson s disease | No dispute reported | 06/30/2026 | 1202533215 |
| Principal investigator 1 | H. Lundbeck A S | $4,116.60 | 12/19/2025 | Non-covered Recipient Entity PARKINSONS DISEASE AND MOVEMENT | AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) | No dispute reported | 06/30/2026 | 1251778631 |
| Principal investigator 1 | H. Lundbeck A S | $7,707.60 | 12/19/2025 | Non-covered Recipient Entity PARKINSONS DISEASE AND MOVEMENT | A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) | No dispute reported | 06/30/2026 | 1251778661 |
| Principal investigator 1 | Ipsen Innovation | $5,120.74 | 12/19/2025 | Non-covered Recipient Entity Parkinsons Disease And Movement Disorders Center Of Boca Raton | A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants | No dispute reported | 06/30/2026 | 1184288166 |
| Principal investigator 1 | Ipsen Innovation | $434.63 | 12/19/2025 | Non-covered Recipient Entity Parkinsons Disease And Movement Disorders Center Of Boca Raton | A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants | No dispute reported | 06/30/2026 | 1184288168 |
| Principal investigator 1 | Ipsen Innovation | $4,460.96 | 12/19/2025 | Non-covered Recipient Entity Parkinsons Disease And Movement Disorders Center Of Boca Raton | A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants | No dispute reported | 06/30/2026 | 1184288170 |
| Principal investigator 1 | Ipsen Innovation | $5,120.74 | 12/19/2025 | Non-covered Recipient Entity Parkinsons Disease And Movement Disorders Center Of Boca Raton | A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants | No dispute reported | 06/30/2026 | 1184288172 |
| Principal investigator 1 | Ipsen Innovation | $4,460.96 | 12/19/2025 | Non-covered Recipient Entity Parkinsons Disease And Movement Disorders Center Of Boca Raton | A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants | No dispute reported | 06/30/2026 | 1184288174 |
| Principal investigator 1 | Ipsen Innovation | $4,008.53 | 12/19/2025 | Non-covered Recipient Entity Parkinsons Disease And Movement Disorders Center Of Boca Raton | A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants | No dispute reported | 06/30/2026 | 1184288176 |
| Principal investigator 1 | Ipsen Innovation | $434.63 | 12/19/2025 | Non-covered Recipient Entity Parkinsons Disease And Movement Disorders Center Of Boca Raton | A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants | No dispute reported | 06/30/2026 | 1184288178 |
| Principal investigator 1 | Ipsen Innovation | $4,460.96 | 12/19/2025 | Non-covered Recipient Entity Parkinsons Disease And Movement Disorders Center Of Boca Raton | A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants | No dispute reported | 06/30/2026 | 1184288180 |
| Principal investigator 1 | Ipsen Innovation | $5,120.74 | 12/19/2025 | Non-covered Recipient Entity Parkinsons Disease And Movement Disorders Center Of Boca Raton | A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants | No dispute reported | 06/30/2026 | 1184288182 |
| Recipient | Amneal Pharmaceuticals LLC | $3,000.00 | 12/18/2025 | Covered Recipient Physician | IPX203-401-23 | No dispute reported | 06/30/2026 | 1220530701 |
| Principal investigator 1 | H. Lundbeck A S | $4,840.20 | 12/11/2025 | Non-covered Recipient Entity PARKINSONS DISEASE AND MOVEMENT | AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) | No dispute reported | 06/30/2026 | 1251778286 |
| Principal investigator 1 | H. Lundbeck A S | $4,409.10 | 12/11/2025 | Non-covered Recipient Entity PARKINSONS DISEASE AND MOVEMENT | A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) | No dispute reported | 06/30/2026 | 1251778366 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $809.00 | 12/05/2025 | Non-covered Recipient Entity PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC | ITI-214-202 | No dispute reported | 06/30/2026 | 1242369009 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $809.00 | 12/05/2025 | Non-covered Recipient Entity PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC | ITI-214-202 | No dispute reported | 06/30/2026 | 1242369011 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $40.45 | 12/05/2025 | Non-covered Recipient Entity PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC | ITI-214-202 | No dispute reported | 06/30/2026 | 1242369033 |
| Principal investigator 1 | ABBVIE INC. | $3,310.24 | 12/04/2025 | Non-covered Recipient Entity PARKINSON S DISEASE AND MOVEMENT | Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson Disease | No dispute reported | 06/30/2026 | 1202527814 |
| Principal investigator 1 | ABBVIE INC. | $8,119.08 | 12/04/2025 | Non-covered Recipient Entity PARKINSON S DISEASE AND MOVEMENT | Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson s Disease | No dispute reported | 06/30/2026 | 1202527816 |
| Recipient | Amneal Pharmaceuticals LLC | $28,000.00 | 12/04/2025 | Covered Recipient Physician | IPX203-401-23 | No dispute reported | 06/30/2026 | 1220530697 |
| Principal investigator 1 | H. Lundbeck A S | $7,051.50 | 12/04/2025 | Non-covered Recipient Entity PARKINSONS DISEASE AND MOVEMENT | A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) | No dispute reported | 06/30/2026 | 1251778086 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $500.00 | 12/04/2025 | Non-covered Recipient Entity PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC | ITI-214-202 | No dispute reported | 06/30/2026 | 1242368515 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $400.00 | 12/04/2025 | Non-covered Recipient Entity PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC | ITI-214-202 | No dispute reported | 06/30/2026 | 1242368533 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $1,280.00 | 12/04/2025 | Non-covered Recipient Entity Parkinson's Disease & Movement Disorders Center of Boca Raton | A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) | No dispute reported | 06/30/2026 | 1244052701 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $4,200.00 | 12/01/2025 | Non-covered Recipient Entity PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC | ITI-214-202 | No dispute reported | 06/30/2026 | 1242368261 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,400.00 | 12/01/2025 | Non-covered Recipient Entity PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC | ITI-214-202 | No dispute reported | 06/30/2026 | 1242368263 |
| Principal investigator 1 | H. Lundbeck A S | $6,814.80 | 11/26/2025 | Non-covered Recipient Entity PARKINSONS DISEASE AND MOVEMENT | A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) | No dispute reported | 06/30/2026 | 1251777761 |
| Principal investigator 1 | ABBVIE INC. | $465.00 | 11/25/2025 | Non-covered Recipient Entity MGPO RADIOLOGY ASSOCIATES | Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma | No dispute reported | 06/30/2026 | 1202525272 |
| Recipient | Amneal Pharmaceuticals LLC | $129,150.04 | 11/20/2025 | Covered Recipient Physician | IPX203-401-23 | No dispute reported | 06/30/2026 | 1220530693 |
| Principal investigator 1 | H. Lundbeck A S | $1,539.00 | 11/14/2025 | Non-covered Recipient Entity PARKINSONS DISEASE AND MOVEMENT | AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) | No dispute reported | 06/30/2026 | 1251777174 |
| Principal investigator 1 | H. Lundbeck A S | $5,188.40 | 11/14/2025 | Non-covered Recipient Entity PARKINSONS DISEASE AND MOVEMENT | A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) | No dispute reported | 06/30/2026 | 1251777231 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $4,747.44 | 11/14/2025 | Non-covered Recipient Entity Parkinson's Disease & Movement Disorders Center of Boca Raton | A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) | No dispute reported | 06/30/2026 | 1244052699 |
| Principal investigator 1 | ABBVIE INC. | $2,240.00 | 11/11/2025 | Non-covered Recipient Entity MGPO RADIOLOGY ASSOCIATES | Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma | No dispute reported | 06/30/2026 | 1202523741 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $7,546.42 | 11/07/2025 | Non-covered Recipient Entity Parkinson's Disease & Movement Disorders Center of Boca Raton | A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) | No dispute reported | 06/30/2026 | 1244052697 |
| Principal investigator 1 | H. Lundbeck A S | $8,978.40 | 11/06/2025 | Non-covered Recipient Entity PARKINSONS DISEASE AND MOVEMENT | A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) | No dispute reported | 06/30/2026 | 1251776550 |
| Principal investigator 1 | ABBVIE INC. | $14,644.44 | 11/04/2025 | Non-covered Recipient Entity PARKINSON S DISEASE AND MOVEMENT | Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson s Disease | No dispute reported | 06/30/2026 | 1202520487 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $154.38 | 10/29/2025 | Non-covered Recipient Entity PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON | Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) | No dispute reported | 06/30/2026 | 1184254789 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $45.90 | 10/29/2025 | Non-covered Recipient Entity PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON | Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) | No dispute reported | 06/30/2026 | 1184254791 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $9.45 | 10/29/2025 | Non-covered Recipient Entity PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON | Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) | No dispute reported | 06/30/2026 | 1184254793 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $45.90 | 10/29/2025 | Non-covered Recipient Entity PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON | Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) | No dispute reported | 06/30/2026 | 1184254795 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $9.45 | 10/29/2025 | Non-covered Recipient Entity PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON | Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) | No dispute reported | 06/30/2026 | 1184254797 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $154.38 | 10/29/2025 | Non-covered Recipient Entity PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON | Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) | No dispute reported | 06/30/2026 | 1184254799 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $248.40 | 10/29/2025 | Non-covered Recipient Entity PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON | Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) | No dispute reported | 06/30/2026 | 1184254801 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $9.45 | 10/29/2025 | Non-covered Recipient Entity PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON | Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) | No dispute reported | 06/30/2026 | 1184254803 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $9.45 | 10/29/2025 | Non-covered Recipient Entity PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON | Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) | No dispute reported | 06/30/2026 | 1184254805 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $109.15 | 10/29/2025 | Non-covered Recipient Entity PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON | Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) | No dispute reported | 06/30/2026 | 1184254807 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $248.40 | 10/29/2025 | Non-covered Recipient Entity PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON | Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) | No dispute reported | 06/30/2026 | 1184254809 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $248.40 | 10/29/2025 | Non-covered Recipient Entity PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON | Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) | No dispute reported | 06/30/2026 | 1184254811 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $9.45 | 10/29/2025 | Non-covered Recipient Entity PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON | Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) | No dispute reported | 06/30/2026 | 1184254813 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $109.15 | 10/29/2025 | Non-covered Recipient Entity PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON | Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) | No dispute reported | 06/30/2026 | 1184254815 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $248.40 | 10/29/2025 | Non-covered Recipient Entity PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON | Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) | No dispute reported | 06/30/2026 | 1184254817 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $109.15 | 10/29/2025 | Non-covered Recipient Entity PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON | Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) | No dispute reported | 06/30/2026 | 1184254819 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $9.45 | 10/29/2025 | Non-covered Recipient Entity PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON | Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) | No dispute reported | 06/30/2026 | 1184254821 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $161.80 | 10/29/2025 | Non-covered Recipient Entity PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON | Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) | No dispute reported | 06/30/2026 | 1184254823 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $154.38 | 10/29/2025 | Non-covered Recipient Entity PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON | Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) | No dispute reported | 06/30/2026 | 1184254825 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $161.80 | 10/29/2025 | Non-covered Recipient Entity PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON | Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) | No dispute reported | 06/30/2026 | 1184254827 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $248.40 | 10/29/2025 | Non-covered Recipient Entity PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON | Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) | No dispute reported | 06/30/2026 | 1184254829 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $161.80 | 10/29/2025 | Non-covered Recipient Entity PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON | Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) | No dispute reported | 06/30/2026 | 1184254831 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $248.40 | 10/29/2025 | Non-covered Recipient Entity PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON | Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) | No dispute reported | 06/30/2026 | 1184254833 |
| Principal investigator 1 | H. Lundbeck A S | $2,271.60 | 10/28/2025 | Non-covered Recipient Entity PARKINSONS DISEASE AND MOVEMENT | A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) | No dispute reported | 06/30/2026 | 1251776336 |
| Principal investigator 1 | H. Lundbeck A S | $500.00 | 10/23/2025 | Non-covered Recipient Entity PARKINSONS DISEASE AND MOVEMENT | A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) | No dispute reported | 06/30/2026 | 1251775958 |
| Principal investigator 1 | H. Lundbeck A S | $16,475.00 | 10/23/2025 | Non-covered Recipient Entity PARKINSONS DISEASE AND MOVEMENT | A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) | No dispute reported | 06/30/2026 | 1251775979 |
| Principal investigator 1 | H. Lundbeck A S | $2,000.00 | 10/23/2025 | Non-covered Recipient Entity PARKINSONS DISEASE AND MOVEMENT | A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) | No dispute reported | 06/30/2026 | 1251775986 |
| Principal investigator 1 | H. Lundbeck A S | $10,000.00 | 10/23/2025 | Non-covered Recipient Entity PARKINSONS DISEASE AND MOVEMENT | A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) | No dispute reported | 06/30/2026 | 1251775990 |
| Principal investigator 1 | H. Lundbeck A S | $1,622.70 | 10/23/2025 | Non-covered Recipient Entity PARKINSONS DISEASE AND MOVEMENT | AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) | No dispute reported | 06/30/2026 | 1251775997 |
| Principal investigator 1 | H. Lundbeck A S | $65,468.00 | 10/23/2025 | Non-covered Recipient Entity PARKINSONS DISEASE AND MOVEMENT | A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) | No dispute reported | 06/30/2026 | 1251776030 |
| Principal investigator 1 | H. Lundbeck A S | $3,889.80 | 10/23/2025 | Non-covered Recipient Entity PARKINSONS DISEASE AND MOVEMENT | A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) | No dispute reported | 06/30/2026 | 1251776046 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $10,500.00 | 10/22/2025 | Non-covered Recipient Entity PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON | Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) | No dispute reported | 06/30/2026 | 1184251728 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,500.00 | 10/22/2025 | Non-covered Recipient Entity PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON | Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) | No dispute reported | 06/30/2026 | 1184251730 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $350.00 | 10/22/2025 | Non-covered Recipient Entity PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON | Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) | No dispute reported | 06/30/2026 | 1184251732 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $350.00 | 10/22/2025 | Non-covered Recipient Entity PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON | Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) | No dispute reported | 06/30/2026 | 1184251734 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $350.00 | 10/22/2025 | Non-covered Recipient Entity PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON | Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) | No dispute reported | 06/30/2026 | 1184251736 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,800.00 | 10/22/2025 | Non-covered Recipient Entity PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON | Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) | No dispute reported | 06/30/2026 | 1184251738 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,500.00 | 10/22/2025 | Non-covered Recipient Entity PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON | Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) | No dispute reported | 06/30/2026 | 1184251740 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $555.00 | 10/22/2025 | Non-covered Recipient Entity PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON | Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) | No dispute reported | 06/30/2026 | 1184251742 |
| Principal investigator 1 | H. Lundbeck A S | $7,185.60 | 10/16/2025 | Non-covered Recipient Entity PARKINSONS DISEASE AND MOVEMENT | A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) | No dispute reported | 06/30/2026 | 1251775777 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $974.23 | 10/16/2025 | Non-covered Recipient Entity Parkinson's Disease & Movement Disorders Center of Boca Raton | A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) | No dispute reported | 06/30/2026 | 1244052695 |
| Principal investigator 1 | Roche TCRC, Inc. | $10,167.30 | 10/15/2025 | Non-covered Recipient Entity PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC | Phase II study in early stage Parkinson s Disease Patients | No dispute reported | 06/30/2026 | 1211637123 |
| Principal investigator 1 | ABBVIE INC. | $8,064.36 | 10/09/2025 | Non-covered Recipient Entity PARKINSON S DISEASE AND MOVEMENT | Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson s Disease | No dispute reported | 06/30/2026 | 1202514719 |
| Principal investigator 1 | ABBVIE INC. | $458.45 | 10/09/2025 | Non-covered Recipient Entity PARKINSON S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC | Open-label Trial in Parkinson s Disease (PD) (TEMPO-4) | No dispute reported | 06/30/2026 | 1202516471 |
| Principal investigator 1 | H. Lundbeck A S | $5,564.70 | 10/09/2025 | Non-covered Recipient Entity PARKINSONS DISEASE AND MOVEMENT | AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) | No dispute reported | 06/30/2026 | 1251775502 |
| Principal investigator 1 | H. Lundbeck A S | $7,956.00 | 10/09/2025 | Non-covered Recipient Entity PARKINSONS DISEASE AND MOVEMENT | A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) | No dispute reported | 06/30/2026 | 1251775524 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $3,773.21 | 10/09/2025 | Non-covered Recipient Entity Parkinson's Disease & Movement Disorders Center of Boca Raton | A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) | No dispute reported | 06/30/2026 | 1244052693 |
| Principal investigator 1 | H. Lundbeck A S | $2,271.60 | 10/03/2025 | Non-covered Recipient Entity PARKINSONS DISEASE AND MOVEMENT | A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) | No dispute reported | 06/30/2026 | 1251775240 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $4,132.31 | 10/03/2025 | Non-covered Recipient Entity Parkinson's Disease & Movement Disorders Center of Boca Raton | A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) | No dispute reported | 06/30/2026 | 1244052691 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $809.00 | 10/02/2025 | Non-covered Recipient Entity PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC | ITI-214-202 | No dispute reported | 06/30/2026 | 1242359854 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $3,185.00 | 10/02/2025 | Non-covered Recipient Entity PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC | ITI-214-202 | No dispute reported | 06/30/2026 | 1242359856 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $3,950.00 | 10/02/2025 | Non-covered Recipient Entity PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC | ITI-214-202 | No dispute reported | 06/30/2026 | 1242359858 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $1,625.00 | 10/02/2025 | Non-covered Recipient Entity PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC | ITI-214-202 | No dispute reported | 06/30/2026 | 1242359860 |
| Principal investigator 1 | H. Lundbeck A S | $3,530.70 | 09/23/2025 | Non-covered Recipient Entity PARKINSONS DISEASE AND MOVEMENT | A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) | No dispute reported | 06/30/2026 | 1251774971 |
| Principal investigator 1 | H. Lundbeck A S | $21,534.30 | 09/23/2025 | Non-covered Recipient Entity PARKINSONS DISEASE AND MOVEMENT | AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) | No dispute reported | 06/30/2026 | 1251774974 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $974.23 | 09/23/2025 | Non-covered Recipient Entity Parkinson's Disease & Movement Disorders Center of Boca Raton | A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) | No dispute reported | 06/30/2026 | 1244052689 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $974.23 | 09/18/2025 | Non-covered Recipient Entity Parkinson's Disease & Movement Disorders Center of Boca Raton | A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) | No dispute reported | 06/30/2026 | 1244052687 |
| Principal investigator 1 | ABBVIE INC. | $1,576.78 | 09/11/2025 | Non-covered Recipient Entity PARKINSON S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC | Open-label Trial in Parkinson s Disease (PD) (TEMPO-4) | No dispute reported | 06/30/2026 | 1202510818 |
| Principal investigator 1 | H. Lundbeck A S | $2,642.40 | 09/11/2025 | Non-covered Recipient Entity PARKINSONS DISEASE AND MOVEMENT | A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) | No dispute reported | 06/30/2026 | 1251774572 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $3,444.00 | 09/08/2025 | Non-covered Recipient Entity PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC | ITI-214-202 | No dispute reported | 06/30/2026 | 1242358684 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $1,392.00 | 09/08/2025 | Non-covered Recipient Entity PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC | ITI-214-202 | No dispute reported | 06/30/2026 | 1242358686 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $3,993.00 | 09/08/2025 | Non-covered Recipient Entity PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC | ITI-214-202 | No dispute reported | 06/30/2026 | 1242358688 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $3,455.00 | 09/08/2025 | Non-covered Recipient Entity PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC | ITI-214-202 | No dispute reported | 06/30/2026 | 1242358690 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $809.00 | 09/08/2025 | Non-covered Recipient Entity PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC | ITI-214-202 | No dispute reported | 06/30/2026 | 1242358692 |
| Principal investigator 1 | H. Lundbeck A S | $26,020.80 | 09/04/2025 | Non-covered Recipient Entity PARKINSONS DISEASE AND MOVEMENT | A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) | No dispute reported | 06/30/2026 | 1251774253 |
| Principal investigator 1 | H. Lundbeck A S | $5,564.70 | 09/04/2025 | Non-covered Recipient Entity PARKINSONS DISEASE AND MOVEMENT | AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) | No dispute reported | 06/30/2026 | 1251774264 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $3,773.21 | 09/04/2025 | Non-covered Recipient Entity Parkinson's Disease & Movement Disorders Center of Boca Raton | A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) | No dispute reported | 06/30/2026 | 1244052847 |
| Principal investigator 1 | ABBVIE INC. | $3,317.40 | 09/03/2025 | Non-covered Recipient Entity PARKINSON S DISEASE AND MOVEMENT | Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson s Disease | No dispute reported | 06/30/2026 | 1202507565 |
| Principal investigator 1 | ABBVIE INC. | $3,310.24 | 09/03/2025 | Non-covered Recipient Entity PARKINSON S DISEASE AND MOVEMENT | Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson Disease | No dispute reported | 06/30/2026 | 1202507567 |
| Principal investigator 1 | H. Lundbeck A S | $16,046.10 | 08/26/2025 | Non-covered Recipient Entity PARKINSONS DISEASE AND MOVEMENT | A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) | No dispute reported | 06/30/2026 | 1251773946 |
| Principal investigator 1 | H. Lundbeck A S | $5,810.40 | 08/26/2025 | Non-covered Recipient Entity PARKINSONS DISEASE AND MOVEMENT | AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) | No dispute reported | 06/30/2026 | 1251773954 |
| Principal investigator 1 | H. Lundbeck A S | $1,936.80 | 08/21/2025 | Non-covered Recipient Entity PARKINSONS DISEASE AND MOVEMENT | AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) | No dispute reported | 06/30/2026 | 1251773755 |
| Principal investigator 1 | H. Lundbeck A S | $5,810.40 | 08/14/2025 | Non-covered Recipient Entity PARKINSONS DISEASE AND MOVEMENT | AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) | No dispute reported | 06/30/2026 | 1251773609 |
| Principal investigator 1 | Roche TCRC, Inc. | $722.00 | 08/14/2025 | Non-covered Recipient Entity PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC | Phase II study in early stage Parkinson s Disease Patients | No dispute reported | 06/30/2026 | 1211637115 |
| Principal investigator 1 | Roche TCRC, Inc. | $1,992.60 | 08/14/2025 | Non-covered Recipient Entity PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC | Phase II study in early stage Parkinson s Disease Patients | No dispute reported | 06/30/2026 | 1211637119 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $14,787.62 | 08/14/2025 | Non-covered Recipient Entity Parkinson's Disease & Movement Disorders Center of Boca Raton | A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) | No dispute reported | 06/30/2026 | 1244052845 |
| Principal investigator 1 | ABBVIE INC. | $10,477.75 | 08/13/2025 | Non-covered Recipient Entity PARKINSON S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC | Open-label Trial in Parkinson s Disease (PD) (TEMPO-4) | No dispute reported | 06/30/2026 | 1202504489 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $1,948.46 | 08/07/2025 | Non-covered Recipient Entity Parkinson's Disease & Movement Disorders Center of Boca Raton | A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) | No dispute reported | 06/30/2026 | 1244052843 |
| Principal investigator 1 | ABBVIE INC. | $2,714.30 | 08/06/2025 | Non-covered Recipient Entity PARKINSON S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC | Fixed-Dose Trial in Early Parkinson s Disease (PD) (TEMPO-1) | No dispute reported | 06/30/2026 | 1202503597 |
| Principal investigator 1 | ABBVIE INC. | $15,959.43 | 08/05/2025 | Non-covered Recipient Entity PARKINSON S DISEASE AND MOVEMENT | Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson s Disease | No dispute reported | 06/30/2026 | 1202502018 |
| Principal investigator 1 | H. Lundbeck A S | $8,182.80 | 07/31/2025 | Non-covered Recipient Entity PARKINSONS DISEASE AND MOVEMENT | AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) | No dispute reported | 06/30/2026 | 1251772891 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $974.23 | 07/31/2025 | Non-covered Recipient Entity Parkinson's Disease & Movement Disorders Center of Boca Raton | A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) | No dispute reported | 06/30/2026 | 1244052841 |
| Recipient | Amneal Pharmaceuticals LLC | $35,167.63 | 07/23/2025 | Covered Recipient Physician | IPX203-401-23 | No dispute reported | 06/30/2026 | 1220530684 |
| Recipient | Amneal Pharmaceuticals LLC | $35,167.63 | 07/23/2025 | Covered Recipient Physician | IPX203-401-23 | No dispute reported | 06/30/2026 | 1220530689 |
| Principal investigator 1 | H. Lundbeck A S | $16,801.20 | 07/17/2025 | Non-covered Recipient Entity PARKINSONS DISEASE AND MOVEMENT | AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) | No dispute reported | 06/30/2026 | 1251772390 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $4,104.38 | 07/17/2025 | Non-covered Recipient Entity Parkinson's Disease & Movement Disorders Center of Boca Raton | A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) | No dispute reported | 06/30/2026 | 1244052839 |
| Principal investigator 1 | H. Lundbeck A S | $7,185.60 | 07/10/2025 | Non-covered Recipient Entity PARKINSONS DISEASE AND MOVEMENT | A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) | No dispute reported | 06/30/2026 | 1251772030 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $3,773.21 | 07/10/2025 | Non-covered Recipient Entity Parkinson's Disease & Movement Disorders Center of Boca Raton | A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) | No dispute reported | 06/30/2026 | 1244052837 |
| Principal investigator 1 | ABBVIE INC. | $2,002.41 | 07/08/2025 | Non-covered Recipient Entity PARKINSON S DISEASE AND MOVEMENT | Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson s Disease | No dispute reported | 06/30/2026 | 1202497274 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $3,950.00 | 07/07/2025 | Non-covered Recipient Entity PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC | ITI-214-202 | No dispute reported | 06/30/2026 | 1242352770 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $1,625.00 | 07/07/2025 | Non-covered Recipient Entity PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC | ITI-214-202 | No dispute reported | 06/30/2026 | 1242352772 |
| Principal investigator 1 | UCB SA | $4,300.00 | 07/04/2025 | Non-covered Recipient Entity PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON | A MULTICENTER PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF UCB0022 IN STUDY PARTICIPANTS WITH ADVANCED Parkinsons DISEASE | No dispute reported | 06/30/2026 | 1246658744 |
| Principal investigator 1 | H. Lundbeck A S | $4,543.20 | 07/03/2025 | Non-covered Recipient Entity PARKINSONS DISEASE AND MOVEMENT | A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) | No dispute reported | 06/30/2026 | 1251771705 |
| Principal investigator 1 | ABBVIE INC. | $3,310.24 | 07/02/2025 | Non-covered Recipient Entity PARKINSON S DISEASE AND MOVEMENT | Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson Disease | No dispute reported | 06/30/2026 | 1202495527 |
| Principal investigator 1 | ABBVIE INC. | $1,500.00 | 07/02/2025 | Non-covered Recipient Entity PARKINSON S DISEASE AND MOVEMENT | Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor | No dispute reported | 06/30/2026 | 1202495529 |
| Principal investigator 1 | H. Lundbeck A S | $2,372.40 | 06/24/2025 | Non-covered Recipient Entity PARKINSONS DISEASE AND MOVEMENT | AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) | No dispute reported | 06/30/2026 | 1251771483 |
| Principal investigator 1 | H. Lundbeck A S | $3,941.00 | 06/24/2025 | Non-covered Recipient Entity PARKINSONS DISEASE AND MOVEMENT | A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) | No dispute reported | 06/30/2026 | 1251771560 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $6,080.77 | 06/24/2025 | Non-covered Recipient Entity Parkinson's Disease & Movement Disorders Center of Boca Raton | A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) | No dispute reported | 06/30/2026 | 1244052835 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $3,258.50 | 06/19/2025 | Non-covered Recipient Entity Parkinson's Disease & Movement Disorders Center of Boca Raton | A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) | No dispute reported | 06/30/2026 | 1244052833 |
| Principal investigator 1 | ABBVIE INC. | $843.75 | 06/17/2025 | Non-covered Recipient Entity PARKINSON S DISEASE AND MOVEMENT | Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor | No dispute reported | 06/30/2026 | 1202491713 |
| Principal investigator 1 | ABBVIE INC. | $2,400.00 | 06/17/2025 | Non-covered Recipient Entity PARKINSON S DISEASE AND MOVEMENT | Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor | No dispute reported | 06/30/2026 | 1202491755 |
| Principal investigator 1 | ABBVIE INC. | $1,000.00 | 06/17/2025 | Non-covered Recipient Entity PARKINSON S DISEASE AND MOVEMENT | Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor | No dispute reported | 06/30/2026 | 1202491757 |
| Principal investigator 1 | ABBVIE INC. | $1,000.00 | 06/17/2025 | Non-covered Recipient Entity PARKINSON S DISEASE AND MOVEMENT | Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor | No dispute reported | 06/30/2026 | 1202491759 |
| Principal investigator 1 | Roche TCRC, Inc. | $13,542.30 | 06/13/2025 | Non-covered Recipient Entity PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC | Phase II study in early stage Parkinson s Disease Patients | No dispute reported | 06/30/2026 | 1211637107 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $14,227.69 | 06/12/2025 | Non-covered Recipient Entity Parkinson's Disease & Movement Disorders Center of Boca Raton | A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) | No dispute reported | 06/30/2026 | 1244052831 |
| Principal investigator 1 | H. Lundbeck A S | $8,460.90 | 06/05/2025 | Non-covered Recipient Entity PARKINSONS DISEASE AND MOVEMENT | A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) | No dispute reported | 06/30/2026 | 1251770836 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $4,104.38 | 06/05/2025 | Non-covered Recipient Entity Parkinson's Disease & Movement Disorders Center of Boca Raton | A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) | No dispute reported | 06/30/2026 | 1244052829 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $3,444.00 | 06/04/2025 | Non-covered Recipient Entity PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC | ITI-214-202 | No dispute reported | 06/30/2026 | 1242348798 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $1,392.00 | 06/04/2025 | Non-covered Recipient Entity PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC | ITI-214-202 | No dispute reported | 06/30/2026 | 1242348800 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $3,950.00 | 06/04/2025 | Non-covered Recipient Entity PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC | ITI-214-202 | No dispute reported | 06/30/2026 | 1242348802 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $1,625.00 | 06/04/2025 | Non-covered Recipient Entity PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC | ITI-214-202 | No dispute reported | 06/30/2026 | 1242348804 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $3,993.00 | 06/04/2025 | Non-covered Recipient Entity PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC | ITI-214-202 | No dispute reported | 06/30/2026 | 1242348806 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $3,455.00 | 06/04/2025 | Non-covered Recipient Entity PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC | ITI-214-202 | No dispute reported | 06/30/2026 | 1242348808 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $3,185.00 | 06/04/2025 | Non-covered Recipient Entity PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC | ITI-214-202 | No dispute reported | 06/30/2026 | 1242348810 |
| Principal investigator 1 | ABBVIE INC. | $3,317.40 | 06/03/2025 | Non-covered Recipient Entity PARKINSON S DISEASE AND MOVEMENT | Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson s Disease | No dispute reported | 06/30/2026 | 1202487631 |
| Principal investigator 1 | ABBVIE INC. | $4,432.24 | 06/03/2025 | Non-covered Recipient Entity PARKINSON S DISEASE AND MOVEMENT | Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson Disease | No dispute reported | 06/30/2026 | 1202489025 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $889.00 | 06/01/2025 | Non-covered Recipient Entity Parkinson's Disease & Movement Disorders Center of Boca Raton | A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) | No dispute reported | 06/30/2026 | 1244052827 |
| Principal investigator 1 | ABBVIE INC. | $543.99 | 05/28/2025 | Non-covered Recipient Entity PARKINSON S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC | Fixed-Dose Trial in Early Parkinson s Disease (PD) (TEMPO-1) | No dispute reported | 06/30/2026 | 1202486539 |
| Principal investigator 1 | ABBVIE INC. | $101.25 | 05/28/2025 | Non-covered Recipient Entity PARKINSON S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC | Fixed-Dose Trial in Early Parkinson s Disease (PD) (TEMPO-1) | No dispute reported | 06/30/2026 | 1202486541 |
| Principal investigator 1 | ABBVIE INC. | $101.25 | 05/28/2025 | Non-covered Recipient Entity PARKINSON S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC | Fixed-Dose Trial in Early Parkinson s Disease (PD) (TEMPO-1) | No dispute reported | 06/30/2026 | 1202486543 |
| Principal investigator 1 | Roche TCRC, Inc. | $304.00 | 05/28/2025 | Non-covered Recipient Entity PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC | Phase II study in early stage Parkinson s Disease Patients | No dispute reported | 06/30/2026 | 1211637102 |
| Principal investigator 1 | H. Lundbeck A S | $5,810.40 | 05/27/2025 | Non-covered Recipient Entity PARKINSONS DISEASE AND MOVEMENT | AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) | No dispute reported | 06/30/2026 | 1251770642 |
| Principal investigator 1 | ABBVIE INC. | $1,500.00 | 05/22/2025 | Non-covered Recipient Entity PARKINSON S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC | Fixed-Dose Trial in Early Parkinson s Disease (PD) (TEMPO-1) | No dispute reported | 06/30/2026 | 1202486021 |
| Principal investigator 1 | H. Lundbeck A S | $3,238.20 | 05/22/2025 | Non-covered Recipient Entity PARKINSONS DISEASE AND MOVEMENT | AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) | No dispute reported | 06/30/2026 | 1251770572 |
| Principal investigator 1 | Ipsen Innovation | $3,785.78 | 05/19/2025 | Non-covered Recipient Entity Parkinsons Disease And Movement Disorders Center Of Boca Raton | A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants | No dispute reported | 06/30/2026 | 1184288164 |
| Principal investigator 1 | Genentech, Inc. | $53,694.00 | 05/16/2025 | Non-covered Recipient Entity PARKINSON'S DISEASE & MOVEMENT DISO | A Phase 2b efficacy safety trial of Prasinezumab in patients with early Parkinson s Disease | No dispute reported | 06/30/2026 | 1211637070 |
| Principal investigator 1 | ABBVIE INC. | $8,555.00 | 05/15/2025 | Non-covered Recipient Entity PARKINSON S DISEASE AND MOVEMENT | Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor | No dispute reported | 06/30/2026 | 1202485053 |
| Principal investigator 1 | H. Lundbeck A S | $1,936.80 | 05/15/2025 | Non-covered Recipient Entity PARKINSONS DISEASE AND MOVEMENT | AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) | No dispute reported | 06/30/2026 | 1251770219 |
| Principal investigator 1 | H. Lundbeck A S | $2,642.40 | 05/15/2025 | Non-covered Recipient Entity PARKINSONS DISEASE AND MOVEMENT | A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) | No dispute reported | 06/30/2026 | 1251770323 |
| Principal investigator 1 | Roche TCRC, Inc. | $250.00 | 05/15/2025 | Non-covered Recipient Entity PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC | Phase II study in early stage Parkinson s Disease Patients | No dispute reported | 06/30/2026 | 1211637111 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $4,921.00 | 05/15/2025 | Non-covered Recipient Entity Parkinson's Disease & Movement Disorders Center of Boca Raton | A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) | No dispute reported | 06/30/2026 | 1244052825 |
| Principal investigator 1 | H. Lundbeck A S | $1,936.80 | 05/08/2025 | Non-covered Recipient Entity PARKINSONS DISEASE AND MOVEMENT | AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) | No dispute reported | 06/30/2026 | 1251770106 |
| Principal investigator 1 | H. Lundbeck A S | $2,271.60 | 05/08/2025 | Non-covered Recipient Entity PARKINSONS DISEASE AND MOVEMENT | A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) | No dispute reported | 06/30/2026 | 1251770127 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $974.23 | 05/08/2025 | Non-covered Recipient Entity Parkinson's Disease & Movement Disorders Center of Boca Raton | A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) | No dispute reported | 06/30/2026 | 1244052823 |
| Principal investigator 1 | ABBVIE INC. | $4,004.82 | 05/07/2025 | Non-covered Recipient Entity PARKINSON S DISEASE AND MOVEMENT | Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson s Disease | No dispute reported | 06/30/2026 | 1202483235 |
| Principal investigator 1 | ABBVIE INC. | $561.00 | 05/06/2025 | Non-covered Recipient Entity PARKINSON S DISEASE AND MOVEMENT | Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson Disease | No dispute reported | 06/30/2026 | 1202481741 |
| Principal investigator 1 | H. Lundbeck A S | $1,936.80 | 05/02/2025 | Non-covered Recipient Entity PARKINSONS DISEASE AND MOVEMENT | AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) | No dispute reported | 06/30/2026 | 1251770011 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $3,993.00 | 05/02/2025 | Non-covered Recipient Entity PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC | ITI-214-202 | No dispute reported | 06/30/2026 | 1242344469 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $3,455.00 | 05/02/2025 | Non-covered Recipient Entity PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC | ITI-214-202 | No dispute reported | 06/30/2026 | 1242344471 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $3,185.00 | 05/02/2025 | Non-covered Recipient Entity PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC | ITI-214-202 | No dispute reported | 06/30/2026 | 1242344473 |
| Principal investigator 1 | H. Lundbeck A S | $1,936.80 | 04/22/2025 | Non-covered Recipient Entity PARKINSONS DISEASE AND MOVEMENT | AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) | No dispute reported | 06/30/2026 | 1251769772 |
| Principal investigator 1 | H. Lundbeck A S | $1,936.80 | 04/17/2025 | Non-covered Recipient Entity PARKINSONS DISEASE AND MOVEMENT | AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) | No dispute reported | 06/30/2026 | 1251769739 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $4,132.31 | 04/15/2025 | Non-covered Recipient Entity Parkinson's Disease & Movement Disorders Center of Boca Raton | A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) | No dispute reported | 06/30/2026 | 1244052819 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $400.00 | 04/15/2025 | Non-covered Recipient Entity Parkinson's Disease & Movement Disorders Center of Boca Raton | A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) | No dispute reported | 06/30/2026 | 1244052821 |
| Principal investigator 1 | H. Lundbeck A S | $12,952.80 | 04/10/2025 | Non-covered Recipient Entity PARKINSONS DISEASE AND MOVEMENT | AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) | No dispute reported | 06/30/2026 | 1251769584 |
| Principal investigator 1 | H. Lundbeck A S | $8,090.10 | 04/10/2025 | Non-covered Recipient Entity PARKINSONS DISEASE AND MOVEMENT | A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) | No dispute reported | 06/30/2026 | 1251769588 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $1,000.00 | 04/10/2025 | Non-covered Recipient Entity Parkinson's Disease & Movement Disorders Center of Boca Raton | A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) | No dispute reported | 06/30/2026 | 1244052817 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $3,444.00 | 04/09/2025 | Non-covered Recipient Entity PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC | ITI-214-202 | No dispute reported | 06/30/2026 | 1242340794 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $1,392.00 | 04/09/2025 | Non-covered Recipient Entity PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC | ITI-214-202 | No dispute reported | 06/30/2026 | 1242340796 |
| Principal investigator 1 | ABBVIE INC. | $8,637.21 | 04/03/2025 | Non-covered Recipient Entity PARKINSON S DISEASE AND MOVEMENT | Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson s Disease | No dispute reported | 06/30/2026 | 1202469311 |
| Principal investigator 1 | ABBVIE INC. | $4,432.24 | 04/03/2025 | Non-covered Recipient Entity PARKINSON S DISEASE AND MOVEMENT | Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson Disease | No dispute reported | 06/30/2026 | 1202469315 |
| Principal investigator 1 | H. Lundbeck A S | $1,936.80 | 04/03/2025 | Non-covered Recipient Entity PARKINSONS DISEASE AND MOVEMENT | AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) | No dispute reported | 06/30/2026 | 1251769444 |
| Principal investigator 1 | ABBVIE INC. | $500.00 | 03/27/2025 | Non-covered Recipient Entity PARKINSON'S DISEASE AND M | A GLOBAL REAL WORLD EVIDENCE STUDY ON THE LONG TERM EFFECTIVENESS OF ABBV-951 IN ADVANCED PARKINSONS DISEASE | No dispute reported | 06/30/2026 | 1202466521 |
| Principal investigator 1 | ABBVIE INC. | $500.00 | 03/27/2025 | Non-covered Recipient Entity PARKINSON S DISEASE AND MOVEMENT | P22-487 - Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson s Disease | No dispute reported | 06/30/2026 | 1202466968 |
| Principal investigator 1 | Roche TCRC, Inc. | $358.00 | 03/27/2025 | Non-covered Recipient Entity PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC | Phase II study in early stage Parkinson s Disease Patients | No dispute reported | 06/30/2026 | 1211637074 |
| Principal investigator 1 | Roche TCRC, Inc. | $365.00 | 03/27/2025 | Non-covered Recipient Entity PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC | Phase II study in early stage Parkinson s Disease Patients | No dispute reported | 06/30/2026 | 1211637078 |
| Principal investigator 1 | Roche TCRC, Inc. | $647.00 | 03/27/2025 | Non-covered Recipient Entity PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC | Phase II study in early stage Parkinson s Disease Patients | No dispute reported | 06/30/2026 | 1211637083 |
| Principal investigator 1 | Roche TCRC, Inc. | $540.00 | 03/27/2025 | Non-covered Recipient Entity PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC | Phase II study in early stage Parkinson s Disease Patients | No dispute reported | 06/30/2026 | 1211637088 |
| Principal investigator 1 | Roche TCRC, Inc. | $875.00 | 03/27/2025 | Non-covered Recipient Entity PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC | Phase II study in early stage Parkinson s Disease Patients | No dispute reported | 06/30/2026 | 1211637091 |
| Principal investigator 1 | Roche TCRC, Inc. | $250.00 | 03/27/2025 | Non-covered Recipient Entity PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC | Phase II study in early stage Parkinson s Disease Patients | No dispute reported | 06/30/2026 | 1211637098 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $974.23 | 03/25/2025 | Non-covered Recipient Entity Parkinson's Disease & Movement Disorders Center of Boca Raton | A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) | No dispute reported | 06/30/2026 | 1244052815 |
| Principal investigator 1 | H. Lundbeck A S | $5,818.50 | 03/20/2025 | Non-covered Recipient Entity PARKINSONS DISEASE AND MOVEMENT | A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) | No dispute reported | 06/30/2026 | 1251768986 |
| Principal investigator 1 | H. Lundbeck A S | $5,175.00 | 03/20/2025 | Non-covered Recipient Entity PARKINSONS DISEASE AND MOVEMENT | AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) | No dispute reported | 06/30/2026 | 1251768991 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $9,653.15 | 03/19/2025 | Non-covered Recipient Entity Parkinson's Disease & Movement Disorders Center of Boca Raton | A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) | No dispute reported | 06/30/2026 | 1244052793 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $1,800.00 | 03/19/2025 | Non-covered Recipient Entity Parkinson's Disease & Movement Disorders Center of Boca Raton | A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) | No dispute reported | 06/30/2026 | 1244052795 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $4,678.00 | 03/19/2025 | Non-covered Recipient Entity Parkinson's Disease & Movement Disorders Center of Boca Raton | A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) | No dispute reported | 06/30/2026 | 1244052797 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $6,775.00 | 03/19/2025 | Non-covered Recipient Entity Parkinson's Disease & Movement Disorders Center of Boca Raton | A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) | No dispute reported | 06/30/2026 | 1244052799 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $1,050.00 | 03/19/2025 | Non-covered Recipient Entity Parkinson's Disease & Movement Disorders Center of Boca Raton | A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) | No dispute reported | 06/30/2026 | 1244052801 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $500.00 | 03/19/2025 | Non-covered Recipient Entity Parkinson's Disease & Movement Disorders Center of Boca Raton | A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) | No dispute reported | 06/30/2026 | 1244052803 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $800.00 | 03/19/2025 | Non-covered Recipient Entity Parkinson's Disease & Movement Disorders Center of Boca Raton | A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) | No dispute reported | 06/30/2026 | 1244052805 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $6,000.00 | 03/19/2025 | Non-covered Recipient Entity Parkinson's Disease & Movement Disorders Center of Boca Raton | A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) | No dispute reported | 06/30/2026 | 1244052807 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $650.00 | 03/19/2025 | Non-covered Recipient Entity Parkinson's Disease & Movement Disorders Center of Boca Raton | A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) | No dispute reported | 06/30/2026 | 1244052809 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $3,360.00 | 03/19/2025 | Non-covered Recipient Entity Parkinson's Disease & Movement Disorders Center of Boca Raton | A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) | No dispute reported | 06/30/2026 | 1244052811 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $3,570.00 | 03/19/2025 | Non-covered Recipient Entity Parkinson's Disease & Movement Disorders Center of Boca Raton | A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) | No dispute reported | 06/30/2026 | 1244052813 |
| Principal investigator 1 | H. Lundbeck A S | $8,182.80 | 03/14/2025 | Non-covered Recipient Entity PARKINSONS DISEASE AND MOVEMENT | AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) | No dispute reported | 06/30/2026 | 1251768752 |
| Principal investigator 1 | ABBVIE INC. | $4,919.07 | 03/13/2025 | Non-covered Recipient Entity PARKINSON S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC | Open-label Trial in Parkinson s Disease (PD) (TEMPO-4) | No dispute reported | 06/30/2026 | 1202463822 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $3,950.00 | 03/07/2025 | Non-covered Recipient Entity PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC | ITI-214-202 | No dispute reported | 06/30/2026 | 1242334662 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $1,625.00 | 03/07/2025 | Non-covered Recipient Entity PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC | ITI-214-202 | No dispute reported | 06/30/2026 | 1242334664 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $3,455.00 | 03/07/2025 | Non-covered Recipient Entity PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC | ITI-214-202 | No dispute reported | 06/30/2026 | 1242334728 |
| Principal investigator 1 | ABBVIE INC. | $2,246.07 | 03/06/2025 | Non-covered Recipient Entity PARKINSON S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC | Open-label Trial in Parkinson s Disease (PD) (TEMPO-4) | No dispute reported | 06/30/2026 | 1202459071 |
| Principal investigator 1 | H. Lundbeck A S | $1,936.80 | 03/06/2025 | Non-covered Recipient Entity PARKINSONS DISEASE AND MOVEMENT | AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) | No dispute reported | 06/30/2026 | 1251768496 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $9,653.15 | 03/06/2025 | Non-covered Recipient Entity Parkinson's Disease & Movement Disorders Center of Boca Raton | A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) | No dispute reported | 06/30/2026 | 1244052791 |
| Principal investigator 1 | Sage Therapeutics, LLC | $9,579.36 | 02/27/2025 | Non-covered Recipient Entity PARKINSONS DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON | Study to Evaluate SAGE-324 in Participants With Essential Tremors | No dispute reported | 06/30/2026 | 1206581010 |
| Principal investigator 1 | H. Lundbeck A S | $3,873.60 | 02/20/2025 | Non-covered Recipient Entity PARKINSONS DISEASE AND MOVEMENT | AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) | No dispute reported | 06/30/2026 | 1251767559 |
| Principal investigator 1 | UCB SA | $40,945.90 | 02/20/2025 | Non-covered Recipient Entity PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON | A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, 18-MONTH PHASE 2A STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF ORAL UCB0599 IN STUDY PARTICIPANTS WITH EARLY Parkinsons DISEASE | No dispute reported | 06/30/2026 | 1246658346 |
| Principal investigator 1 | UCB SA | $26,761.00 | 02/19/2025 | Non-covered Recipient Entity PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON | A dose-blinded extension study to evaluate the long-term efficacy, safety, and tolerability of UCB0599 in study participants with Parkinsons disease | No dispute reported | 06/30/2026 | 1246657578 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $3,993.00 | 02/07/2025 | Non-covered Recipient Entity PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC | ITI-214-202 | No dispute reported | 06/30/2026 | 1242330275 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $809.00 | 02/07/2025 | Non-covered Recipient Entity PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC | ITI-214-202 | No dispute reported | 06/30/2026 | 1242330277 |
| Principal investigator 1 | H. Lundbeck A S | $3,873.60 | 02/06/2025 | Non-covered Recipient Entity PARKINSONS DISEASE AND MOVEMENT | AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) | No dispute reported | 06/30/2026 | 1251767148 |
| Principal investigator 1 | Sage Therapeutics, LLC | $12,258.71 | 02/06/2025 | Non-covered Recipient Entity PARKINSONS DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON | A Study to Evaluate the Long-term Safety and Tolerability of SAGE-324 in Participants With Essential Tremor | No dispute reported | 06/30/2026 | 1206580426 |
| Principal investigator 1 | H. Lundbeck A S | $6,246.00 | 01/29/2025 | Non-covered Recipient Entity PARKINSONS DISEASE AND MOVEMENT | AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) | No dispute reported | 06/30/2026 | 1251766765 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $8,678.92 | 01/29/2025 | Non-covered Recipient Entity Parkinson's Disease & Movement Disorders Center of Boca Raton | A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) | No dispute reported | 06/30/2026 | 1244052789 |
| Principal investigator 1 | H. Lundbeck A S | $75.71 | 01/27/2025 | Non-covered Recipient Individual | A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) | No dispute reported | 06/30/2026 | 1251778854 |
| Principal investigator 1 | H. Lundbeck A S | $99.80 | 01/27/2025 | Non-covered Recipient Individual | A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) | No dispute reported | 06/30/2026 | 1251778862 |
| Principal investigator 1 | H. Lundbeck A S | $145.23 | 01/27/2025 | Non-covered Recipient Individual | A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) | No dispute reported | 06/30/2026 | 1251778870 |
| Principal investigator 1 | H. Lundbeck A S | $208.55 | 01/27/2025 | Non-covered Recipient Individual | A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) | No dispute reported | 06/30/2026 | 1251778881 |
| Principal investigator 1 | H. Lundbeck A S | $315.21 | 01/27/2025 | Non-covered Recipient Individual | A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) | No dispute reported | 06/30/2026 | 1251778893 |
| Principal investigator 1 | H. Lundbeck A S | $928.31 | 01/27/2025 | Non-covered Recipient Individual | A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) | No dispute reported | 06/30/2026 | 1251778902 |
| Principal investigator 1 | H. Lundbeck A S | $7,117.20 | 01/17/2025 | Non-covered Recipient Entity PARKINSONS DISEASE AND MOVEMENT | AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) | No dispute reported | 06/30/2026 | 1251766562 |
| Principal investigator 1 | ABBVIE INC. | $7,511.61 | 01/16/2025 | Non-covered Recipient Entity PARKINSON S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC | Open-label Trial in Parkinson s Disease (PD) (TEMPO-4) | No dispute reported | 06/30/2026 | 1202439746 |
| Principal investigator 1 | H. Lundbeck A S | $4,309.20 | 01/09/2025 | Non-covered Recipient Entity PARKINSONS DISEASE AND MOVEMENT | AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) | No dispute reported | 06/30/2026 | 1251766466 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $3,444.00 | 01/08/2025 | Non-covered Recipient Entity PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC | ITI-214-202 | No dispute reported | 06/30/2026 | 1242328468 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $1,392.00 | 01/08/2025 | Non-covered Recipient Entity PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC | ITI-214-202 | No dispute reported | 06/30/2026 | 1242328492 |